Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. - Wikidata - wikimedia - TriplyDB

Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.

Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.

http://www.wikidata.org/entity/Q35051683

about

Pharmacotherapy of aggression in children and adolescents: efficacy and effect size Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function.Disruptive mood dysregulation disorder: current insights Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.Attention-deficit-hyperactivity disorder: an update.Olanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens.Managing attention deficit/hyperactivity disorder: unmet needs and future directions Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics Experts' recommendations for treating maladaptive aggression in youth.Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines.Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies.A Randomized Clinical Trial of an Integrative Group Therapy for Children With Severe Mood Dysregulation.Review of antipsychotics in children and adolescents.Evidence base for practice: reduction of restraint and seclusion use during child and adolescent psychiatric inpatient treatment.Impulsive Aggression as a Comorbidity of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.Antipsychotic treatment patterns and aggressive behavior among adolescents in residential facilities.Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial.Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.Pharmacological treatment of pathologic aggression in children.Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.Child and adolescent psychiatrists' attitudes and practices prescribing second generation antipsychotics What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.After out-of-home mental health treatment: atypical antipsychotic medication use and the probability of returning to treatment.Evidence based administration of risperidone and paliperidone for the treating conduct disorder.Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis.Atypical antipsychotics for disruptive behaviour disorders in children and youths.Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more.Diagnoses and antipsychotic treatment among youths in a public mental health system.Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey.Lessons from an investigation of seclusion at an older adolescent inpatient unit.Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings.Use of clozapine in a state child and adolescent psychiatric hospital.

P2860

Q24648097-8F0D8B9F-C5C9-48D3-98CB-9059F88F357B Q27313333-323F4F8F-6C93-4D96-A57D-E95B97B7DA0C Q28069569-0CA74644-0E05-4160-925F-76B0FFBFBFB3 Q28238719-9B0FEA96-09E6-44CA-BFC8-6E217EBE0BC2 Q28287983-DD568A9A-C48A-45F0-9E27-6548D8FDE209 Q33694959-03CF1717-797F-4D51-97F5-D99D6EDC943B Q34194447-BB50B7FD-F6A9-4E57-92C2-408AB363B205 Q34983475-464CB7A8-B9F1-4CCC-8F74-EBF0E4391E4E Q35021488-58D350DC-67D8-4FC1-BD6B-9775137B2A0B Q35575707-13C38BAC-BE40-41C5-AB6D-E415CF8C3955 Q35641776-EBC68FB4-237E-464F-AB34-E73102D32548 Q35757728-73F10017-CAB9-49AB-A70C-761C7C44BA9C Q35801186-FE5CE52A-74CF-4331-B2B4-6782C2D90B83 Q36233555-FCF6C270-F159-4674-B8CC-C92642E944BB Q36594953-79A38DDF-4211-4408-8D58-BD41BBFF482F Q36610730-60F47B84-10D7-4696-BAD8-732A4707664D Q36613868-A15CE23A-B4C6-4539-AA42-D72D81CBFCCF Q36623264-9A731F04-6A81-4F98-B45D-748538631BA1 Q36654483-258881B6-4438-4135-B21D-9D97EF1BE7AD Q36799433-727EA9B1-2ED1-4947-A8DA-0F190C006B7F Q36949869-E43EC583-A47D-4C23-A18A-78FB1912EE82 Q36965451-345A3762-EE61-4760-9EA9-89B456686B20 Q37127437-7E98EA4A-C207-4053-B70C-A852B2EA22D5 Q37145883-B6AB0FF9-E032-4F03-868C-DB1CA7C4AA17 Q37236402-7CA4A15C-98F2-4DDB-BE1B-BA15DEB612EB Q37667623-3FAFD91E-3D97-4B88-9E80-E00A258C2E29 Q37699333-449FEE49-F83C-498A-A289-A2F6E2EAB602 Q37791316-6D48B23F-A408-439D-992C-0052FF26C20A Q37920762-012D7918-DDC8-4540-93B4-BF2F132A1406 Q38187654-A7A8CFF0-4E7E-4EB3-BCE6-395ADFA08401 Q38448948-ACC2B1B4-E8B6-40D5-BD2A-F1E5102E1BE3 Q38605488-893311AA-3BC8-4127-B2C4-2027138EB68E Q38632745-1CEC7B8A-62D1-4DAF-AC67-8EBA827D6B5D Q39332587-679A76F6-5A89-4827-8517-3655ED453250 Q40355983-B4180E0D-D78A-45A4-A806-A167F92DEFD1 Q45369595-3C33C0EE-401B-4CFA-BECD-4B69B25D7EFF Q46482006-287299C9-A941-49F3-9110-A24B09BAD51F Q46593809-3C46A4AF-CF4A-4962-AB30-205296379F03 Q47416741-4D0FF5BB-691E-4264-9947-A89C4E6B8DA0 Q50732813-D7A38E1A-7DF1-4328-B793-095730671FC2

P2860

Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.

http://www.wikidata.org/entity/Q35051683

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Treatment recommendations for ...... essive youth (TRAAY). Part II.

@ast

Treatment recommendations for ...... essive youth (TRAAY). Part II.

@en

type

label

Treatment recommendations for ...... essive youth (TRAAY). Part II.

@ast

Treatment recommendations for ...... essive youth (TRAAY). Part II.

@en

prefLabel

Treatment recommendations for ...... essive youth (TRAAY). Part II.

@ast

Treatment recommendations for ...... essive youth (TRAAY). Part II.

@en

P1433

Q35051683-05FC08FD-8CEC-4FD3-9D2B-8ECE6BE4E0E9

P1476

Q35051683-AFAEC51C-7897-4DE2-8C3E-5D07F67A8B22

P2093

Q35051683-0C2CC628-8596-4A51-A1DF-77FCAD40625F

Q35051683-127AD9B0-2173-4949-9E0A-1E3876453E0B

Q35051683-1796DB6B-7299-4B4C-8644-5D5913F7161F

Q35051683-4FDC631B-25BE-4CCD-BC46-66B6D529311E

Q35051683-50932873-6A18-4970-828F-3C828937104D

Q35051683-5AC338D9-4E80-41F9-A18E-2B5096A40188

Q35051683-5D62EF11-3191-48D2-A87E-BA435D9C6E60

Q35051683-6C953520-06B2-467F-9566-F51E984A3DE3

Q35051683-719096FE-AD12-4C86-92BF-8CDCB396FF62

Q35051683-832DA937-B180-4E5C-9846-EE27055B3F05

P304

Q35051683-A21A1D73-7242-4E1A-8C05-49DCA3D7653A

P31

Q35051683-BA843DF6-E3D9-4F82-8502-A3D9D0A394F5

P356

Q35051683-FAB42ECD-646A-4DE6-B7EA-4B72046E66E8

P433

Q35051683-8A9A53A1-A808-449B-B29B-FF56118288B1

P478

Q35051683-23DBC9C2-22B3-4862-8C04-A3FB97ACBCB5

P577

Q35051683-C12C3E01-E408-4F9C-8A16-E2CA87A2CE06

P5875

Q35051683-8781AECD-3DDB-47B8-AF5C-D87218C244FF

P698

Q35051683-66853DB9-BD96-4BE6-83FB-03574DCA5C43

P356

00004583-200302000-00008

P1433

Journal of the American Academy of Child and Adolescent Psychiatry

P1476

Treatment recommendations for ...... essive youth (TRAAY). Part II.

@en

P2093

Albert Derivan

http://www.w3.org/2001/XMLSchema#string

Chip J Felton

http://www.w3.org/2001/XMLSchema#string

David M Rube

http://www.w3.org/2001/XMLSchema#string

Elizabeth Pappadopulos

http://www.w3.org/2001/XMLSchema#string

Harvey Kranzler

http://www.w3.org/2001/XMLSchema#string

James C Macintyre Ii

http://www.w3.org/2001/XMLSchema#string

Jeffrey Sverd

http://www.w3.org/2001/XMLSchema#string

Laurence Greenhill

http://www.w3.org/2001/XMLSchema#string

Lin Sikich

http://www.w3.org/2001/XMLSchema#string

M Lynn Crismon

http://www.w3.org/2001/XMLSchema#string

P304

145-161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00004583-200302000-00008

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10936887

http://www.w3.org/2001/XMLSchema#string

P698

12544174

http://www.w3.org/2001/XMLSchema#string